AstraZeneca’s Imfinzi Extends Survival For NonSmall Cell Lung Cancer Patients

NewsA planned interim analysis conducted by an independent committee concluded that the drug met its second of two primary endpoints by showing statistically significant overall survival in patients r…
Read the full story: Bioportfolio Latest News